Reducing dose to the lungs through loosing target dose homogeneity requirement for radiotherapy of non small cell lung cancer

被引:9
|
作者
Miao, Junjie
Yan, Hui
Tian, Yuan
Ma, Pan
Liu, Zhiqiang
Li, Minghui
Ren, Wenting
Chen, Jiayun
Zhang, Ye
Dai, Jianrong [1 ]
机构
[1] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Radiat Oncol, Beijing, Peoples R China
来源
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS | 2017年 / 18卷 / 06期
基金
中国国家自然科学基金;
关键词
IMRT; non small cell lung cancer; plan optimization; target dose homogeneity; treatment planning; INTENSITY-MODULATED RADIOTHERAPY; STEREOTACTIC BODY RADIOTHERAPY; TUMOR-CONTROL PROBABILITY; RADIATION PNEUMONITIS; NSCLC PATIENTS; IMRT; VOLUME; THERAPY; DISTRIBUTIONS; PARAMETERS;
D O I
10.1002/acm2.12200
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system. The dose homogeneity of target was controlled by constraints on the maximum and uniform doses of target volume. One IMRT plan was made with homogeneous target dose (the resulting target dose was within 95%-107% of the prescribed dose), while another IMRT plan was made with inhomogeneous target dose (the resulting target dose was more than 95% of the prescribed dose). During plan optimization, the dose of cord and heart in two types of IMRT plans were kept nearly the same. The doses of lungs, PTV and organs at risk (OARs) between two types of IMRT plans were compared and analyzed quantitatively. For all patients, the lung dose was decreased in the IMRT plans with inhomogeneous target dose. On average, the mean dose, V5, V20, and V30 of lung were reduced by 1.4 Gy, 4.8%, 3.7%, and 1.7%, respectively, and the dose to normal tissue was also reduced. These reductions in DVH values were all statistically significant (P < 0.05). There were no significant differences between the two IMRT plans on V25, V30, V40, V50 and mean dose for heart. The maximum doses of cords in two type IMRT plans were nearly the same. IMRT plans with inhomogeneous target dose could protect lungs better and may be considered as a choice for treating NSCLC.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 50 条
  • [1] Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer
    Schwarz, M
    Alber, M
    Lebesque, JV
    Mijnheer, BJ
    Damen, EMF
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02): : 561 - 570
  • [2] Influence of dose calculation algorithms on isotoxic dose-escalation of non-small cell lung cancer radiotherapy
    Panettieri, Vanessa
    Malik, Zafar I.
    Eswar, Chinnamani V.
    Landau, David B.
    Thornton, John M. C.
    Nahum, Alan E.
    Mayles, W. Philip M.
    Fenwick, John D.
    RADIOTHERAPY AND ONCOLOGY, 2010, 97 (03) : 418 - 424
  • [3] Dose-effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients
    Li, Fei
    Jiang, Hairong
    Bu, Mingwei
    Mu, Xin
    Zhao, Hongfu
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [4] DOSE-VOLUME COMPARISON OF PROTON RADIOTHERAPY AND STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER
    Kadoya, Noriyuki
    Obata, Yasunori
    Kato, Takahiro
    Kagiya, Masaru
    Nakamura, Tatsuya
    Tomoda, Takuya
    Takada, Akinori
    Takayama, Kanako
    Fuwa, Nobukazu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1225 - 1231
  • [5] Dose–effect relationship of stereotactic body radiotherapy in non-small cell lung cancer patients
    Fei Li
    Hairong Jiang
    Mingwei Bu
    Xin Mu
    Hongfu Zhao
    Radiation Oncology, 17
  • [6] CONSEQUENCES OF ANATOMIC CHANGES AND RESPIRATORY MOTION ON RADIATION DOSE DISTRIBUTIONS IN CONFORMAL RADIOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG CANCER
    Britton, Keith R.
    Starkschall, George
    Liu, Helen
    Chang, Joe Y.
    Bilton, Stephen
    Ezhil, Muthuveni
    John-Baptiste, Sandra
    Kantor, Michael
    Cox, James D.
    Komaki, Ritsuko
    Mohan, Radhe
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (01): : 94 - 102
  • [7] Treatment planning and outcomes effects of reducing the preferred mean esophagus dose for conventionally fractionated non-small cell lung cancer radiotherapy
    Yorke, Ellen D.
    Thor, Maria
    Gelblum, Daphna Y.
    Gomez, Daniel R.
    Rimner, Andreas
    Shaverdian, Narek
    Shepherd, Annemarie F.
    Simone, Charles B., II
    Wu, Abraham
    McKnight, Dominique
    Jackson, Andrew
    JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2021, 22 (02): : 42 - 48
  • [8] POTENTIAL OF ADAPTIVE RADIOTHERAPY TO ESCALATE THE RADIATION DOSE IN COMBINED RADIOCHEMOTHERAPY FOR LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Guckenberger, Matthias
    Wilbert, Juergen
    Richter, Anne
    Baier, Kurt
    Flentje, Michael
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (03): : 901 - 908
  • [9] Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer
    De Ruysscher, Dirk
    Dehing, Cary
    Yu, Shipeng
    Wanders, Rinus
    Ollers, Michel
    Dingemans, Anne-Marie C.
    Bootsma, Gerben
    Hochstenbag, Monique
    Geraedts, Wiel
    Pitz, Cordula
    Simons, Jean
    Boersma, Liesbeth
    Borger, Jacques
    Dekker, Andre
    Lambin, Philippe
    RADIOTHERAPY AND ONCOLOGY, 2009, 91 (03) : 353 - 359
  • [10] Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer
    Wada, Kentaro
    Kishi, Noriko
    Kanayama, Naoyuki
    Hirata, Takero
    Morimoto, Masahiro
    Konishi, Koji
    Imamura, Fumio
    Teshima, Teruki
    Ogawa, Kazuhiko
    ANTICANCER RESEARCH, 2018, 38 (10) : 5951 - 5958